Bradley G. Somer MDMedical Oncologist; President, West Cancer Center and Research Institute; Associate Professor of Hematology/Oncology, University of Tennessee Health Science Center, Memphis, Tennessee
Dr. Brad Somer, a medical oncologist in Memphis, Tennessee, is the President of the West Cancer Center and Research Institute, where he has practiced since 2002 after completing his fellowship training in hematology/oncology at the University of Pennsylvania Cancer Center in Philadelphia. He is one of the leaders of the most renowned multi-disciplinary comprehensive cancer center servicing the mid-south. He also serves as an assistant professor of hematology/oncology at the University of Tennessee Health Science Center.
Dr. Somer, is actively involved in clinical research in the gastrointestinal/genitourinary clinical trials program. He also serves on the NCCN panel for kidney cancer.
Dr. Somer earned his medical degree from the Albert Einstein College of Medicine in New York, with a Distinction in Research. He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While at the University of Pennsylvania, he served as assistant editor of OncoLink, a leading and award-winning cancer information website. He received his MBA at U Mass Amherst with a healthcare focus in conjunction with the American Association of Physician Leadership.
Assistant Professor, Hematology/Oncology, University of Tennessee Health Science Center; Senior Partner, West Clinic, Memphis, Tennessee
MD: Albert Einstein College of Medicine, New York
Fellowship (hematology/oncology):University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
DisclosuresDr. Somer does not have any disclosures.
Recent Contributions to PracticeUpdate:
- Clinicopathologic Characteristics and Prognosis of Xp11.2 Translocation Renal Cell Carcinoma
- Novel Treatment Options for RCC From ASCO 2017: A Review
- ASCO 2017: Abstract Recommendations From Dr. Bradley Somer—Renal Cell Carcinoma
- Adjuvant Therapy for High-Risk Localized Kidney Cancer
- Collecting Duct Carcinoma of the Kidney
- MY APPROACH to Dosing Schedules for Sunitinib
- Outcomes of Metastatic Papillary Renal Cell Carcinoma
- Survival Outcomes in Patients With Non–Clear Cell Renal Cell Carcinoma Treated in Clinical Trials
- Putting ctDNA Profiling to Use in Metastatic RCC
- Evolution of Circulating Tumor DNA Profile from First-Line to Subsequent Therapy in mRCC